Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 17, 2026
The DEA synthetic cannabinoids Schedule I placement 2026 marks significant regulatory changes affecting clinical and legal frameworks. This update highlights the classification of several synthetic cannabinoids as Schedule I substances. These actions…
Irafamdastat: Can Dual FAAH/MAGL Inhibition Revive Endocannabinoid Drug Discovery …
✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPainAnxietyNeurologyMental HealthSafetyIndustry Why This Matters Irafamdastat’s dual inhibition of FAAH and…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone due to its high abuse potential and lack of accepted medical use. This regulatory action highlights ongoing challenges in controlling novel psychoactive substances.…
What New Research Says About Cannabis And Testosterone
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyMental HealthTHCCBDAgingNeurology Why This Matters Clinicians need current evidence on cannabis’s…
DEA Emergency Scheduling: Temporary Placement of 2-Fluorodeschloroketamine
The DEA emergency scheduling controlled substances action temporarily places 2-fluorodeschloroketamine in Schedule I due to abuse potential. This update highlights regulatory efforts to control emerging synthetic ketamine analogs. Clinicians should be…
Medical Cannabis Linked to Improvements in Pain, Sleep and Nighttime Urination in …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PainSleepNeurologyResearchTHCCBDSafety Why This Matters This study provides clinical evidence that medical cannabis may…
DEA Update on Diphenidine Scheduling in Controlled Substances Act
The DEA scheduling diphenidine update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This regulatory action highlights challenges in controlling novel synthetic dissociatives. Clinicians should stay informed…
California Senate Committee Advances Bill Clarifying Cannabis and …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyCBDHempSafetyIndustryResearchPain Clinical Summary # Clinical Summary This California legislative action clarifies…
#education | Sandra Milena Carrillo Gomez MD MHSM Med. Cannabis Specialist
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchIndustryPolicySafetyNeurologyMental HealthDosing Clinical Summary # Clinical Summary This article summarizes key…
Medical Cannabis Linked to Improvements in Parkinson’s Non-Motor Symptoms
Medical cannabis parkinsons non-motor symptoms may offer relief for pain, sleep disturbances, and nighttime urination. This observational study suggests potential benefits for Parkinson’s patients. Further research is needed to confirm these findings.